Zobrazeno 1 - 10
of 225
pro vyhledávání: '"M Unverdorben"'
Autor:
M. Unverdorben, C. von Heymann, A. Santamaria, M. Saxena, T. Vanassche, J. Jin, P. Laeis, R. Wilkins, C. Chen, P. Colonna
Publikováno v:
BMC Cardiovascular Disorders, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background Annually > 10% of patients with atrial fibrillation on oral anticoagulation undergo invasive procedures. Optimal peri-procedural management of anticoagulation, as judged by major bleeding and thromboembolic events, especially in t
Externí odkaz:
https://doaj.org/article/2f270912a4ba4504ae4f0811967c6220
Autor:
X Y Guo, J Du, H Hiroshi, Y Yang, M X Wu, W C Qu, X B Han, Z F Wang, J Jin, P Zhang, Z Zhang, M Q Liu, M Unverdorben, C Chen, C S Ma
Publikováno v:
Europace. 25
Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China. Background The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) edox
Autor:
M. Unverdorben, C. von Heymann, A. Santamaria, M. Saxena, T. Vanassche, J. Jin, P. Laeis, R. Wilkins, C. Chen, P. Colonna
Publikováno v:
BMC Cardiovascular Disorders, Vol 21, Iss 1, Pp 1-1 (2021)
An amendment to this paper has been published and can be accessed via the original article.
Externí odkaz:
https://doaj.org/article/13459de09d1d4df197efc2c9f50e552f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J Siller-Matula, M Unverdorben, C C Wang, Y Koretsune, L Pecen, A Borrow, C Chen, P Kirchhof, R De Caterina
Publikováno v:
European Heart Journal. 43
Background Heart failure (HF) occurs in approximately 26% of patients with atrial fibrillation (AF). Real-world data of oral anticoagulation with edoxaban in AF patients with HF history are limited. Purpose To compare edoxaban effectiveness and safet
Autor:
R De Caterina, M Unverdorben, B C Lee, T Yamashita, W S Lin, C C Wang, L Pecen, A Borrow, C Chen, P Kirchhof
Publikováno v:
European Heart Journal. 43
Background Atrial fibrillation (AF) patients with a history of ischaemic stroke (IS) have a higher risk for recurrent IS events and were largely excluded from the pivotal, randomised, controlled phase 3 trials on oral anticoagulants. Thus, the effect
Autor:
V Russo, C C Wang, M Unverdorben, T Yamashita, L Pecen, A Borrow, C Chen, P Kirchhof, R De Caterina
Publikováno v:
European Heart Journal. 43
Background Atrial fibrillation patients with a history of major bleeding (MB) are at high risk of future bleeding events; this history was an exclusion criterion in pivotal phase 3 trials of anticoagulation for stroke prevention. Real-world edoxaban
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
M Saxena, C Von Heymann, A Santamaria, J Jin, C Chen, A Borrow, T Vanassche, M Unverdorben, P Colonna
Publikováno v:
EP Europace. 24
Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Daiichi Sankyo Background Patients with atrial fibrillation (AF) or venous thromboembolism (VTE) receiving long-term direct oral anticoagulant (DOAC) therapy u
Autor:
D Morrone, C Chen, L Dinshaw, W Jiang, Y.-H Kim, P Kirchhof, Y Koretsune, L Pecen, P.-E Reimitz, C.-C Wang, T Yamashita, M Unverdorben, R De Caterina
Publikováno v:
European Heart Journal. 42
Background The ESC atrial fibrillation management guidelines recommend a risk-based approach to oral anticoagulant (OAC) therapy. How clinical practice aligns with these recommendations is of interest. Purpose To analyse real world data from Global E